Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,743.60 | 30.00 | -0.34% |
| CAC 40 | 7,691.55 | 134.24 | 1.78% |
| DAX 40 | 24,033.22 | 383.92 | 1.62% |
| Dow JONES (US) | 43,819.27 | 432.43 | 1.00% |
| FTSE 100 | 8,798.91 | 63.31 | 0.72% |
| HKSE | 24,284.15 | 41.25 | -0.17% |
| NASDAQ | 20,273.46 | 105.55 | 0.52% |
| Nikkei 225 | 40,150.79 | 566.21 | 1.43% |
| NZX 50 Index | 12,583.59 | 103.54 | 0.83% |
| S&P 500 | 6,173.07 | 32.05 | 0.52% |
| S&P/ASX 200 | 8,514.20 | 36.60 | -0.43% |
| SSE Composite Index | 3,424.23 | 24.23 | -0.70% |